Developers have married gene-modulating oligonucleotides with the targeted precision of antibodies, and the first filings using such conjugates in Duchenne muscular dystrophy are imminent. Author information Authors and Affiliations Dublin, Ireland Cormac Sheridan Rights and permissions About this article Cite this article Sheridan, C. Now with oligos: antibody–oligonucleotide conjugates are the new drug modality to...